Discovery of PTB6003, a Next‑Generation Cereblon E3 Ligase Modulator with Potent Activity in Lenalidomide‑Refractory Multiple Myeloma (ICBMT 2026) - Oct 8, 2026 - Abstract #PP05‑07; "PTB exhibits profound anti‑myeloma efficacy and successfully overcomes conventional CELMoD resistance in both preclinical models and primary patient samples. These findings highlight PTB as a highly promising therapeutic candidate for the treatment of multiple myeloma, particularly in relapsed or refractory settings. Keywords: PTB6003, Multiple Myeloma, Lenalidomide, Mezigdomide, CELMoD"
Hematological Malignancies • Multiple Myeloma • Targeted Protein Degradation • ANXA5 • CRBN • GSPT1 • SDC1
|
|
Van‑Tan Nguyen 1, 2; Manh‑Cuong Vo 2; Thuy Nguyen Thi 1; Van‑Dinh‑Huan Tran 1, 2; Ho Cheol Jang 3; Mihee Kim 3; Ga‑Young Song 3; Seo‑Yeon Ahn 3; Jae‑Sook Ahn 3; Deok‑Hwan Yang 3; Hyeoung‑Joon Kim 3; Je‑Jung Lee 1, 2, 3; Sung‑Hoon Jung 2, 3
|